Posttranscriptional regulation of IL-23 expression by IFN-γ through tristetraprolin

Journal of Immunology

Volumn 186, Issue 11, 2011, Pages 6454-6464

  Qian, Xuesong ^a   Ning, Huan ^a   Zhang, Jidong ^a   Hoft, Daniel F ^a   Stumpo, Deborah J ^b   Blackshear, Perry J ^b   Liu, Jianguo ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 23; MESSENGER RNA; TRISTETRAPROLIN;

3' UNTRANSLATED REGION; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; GENE DELETION; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE REPRESSION; IMMUNOPRECIPITATION; MACROPHAGE; MOUSE; NONHUMAN; PLASMID; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEPHOSPHORYLATION; PROTEIN PHOSPHORYLATION; RNA DEGRADATION; RNA STABILITY; SIGNAL TRANSDUCTION; TH17 CELL;

3' UNTRANSLATED REGIONS; ANIMALS; BASE SEQUENCE; BLOTTING, WESTERN; CELL LINE; DENDRITIC CELLS; FEMALE; GENE EXPRESSION REGULATION; INTERFERON-GAMMA; INTERLEUKIN-12; INTERLEUKIN-12 SUBUNIT P35; INTERLEUKIN-23; INTERLEUKIN-23 SUBUNIT P19; LIPOPOLYSACCHARIDES; MALE; MICE; MICE, KNOCKOUT; MOLECULAR SEQUENCE DATA; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA STABILITY; TRANSCRIPTION, GENETIC; TRISTETRAPROLIN;

EID: 79958070748     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1002672     Document Type: Article

References (46)

1. Oppmann, B., R. Lesley, B. Blom, J. C. Timans, Y. Xu, B. Hunte, F. Vega, N. Yu, J. Wang, K. Singh, et al. 2000. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 13: 715-725.
2. Kastelein, R. A., C. A. Hunter, and D. J. Cua. 2007. Discovery and biology of IL- 23 and IL-27: related but functionally distinct regulators of inflammation. Annu. Rev. Immunol. 25: 221-242.
3. Cocco, C., S. Canale, C. Frasson, E. Di Carlo, E. Ognio, D. Ribatti, I. Prigione, G. Basso, and I. Airoldi. 2010. Interleukin-23 acts as antitumor agent on childhood B-acute lymphoblastic leukemia cells. Blood 116: 3887-3898.
4. Lee, E., W. L. Trepicchio, J. L. Oestreicher, D. Pittman, F. Wang, F. Chamian, M. Dhodapkar, and J. G. Krueger. 2004. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J. Exp. Med. 199: 125-130.
5. Vaknin-Dembinsky, A., K. Balashov, and H. L. Weiner. 2006. IL-23 is increased in dendritic cells in multiple sclerosis and down-regulation of IL-23 by antisense oligos increases dendritic cell IL-10 production. J. Immunol. 176: 7768-7774.
6. Schmidt, C., T. Giese, B. Ludwig, I. Mueller-Molaian, T. Marth, S. Zeuzem, S. C. Meuer, and A. Stallmach. 2005. Expression of interleukin-12- related cytokine transcripts in inflammatory bowel disease: elevated interleukin-23p19 and interleukin-27p28 in Crohn's disease but not in ulcerative colitis. Inflamm. Bowel Dis. 11: 16-23.
7. Kim, H. R., H. S. Kim, M. K. Park, M. L. Cho, S. H. Lee, and H. Y. Kim. 2007. The clinical role of IL-23p19 in patients with rheumatoid arthritis. Scand. J. Rheumatol. 36: 259-264.
8. Kim, H. R., M. L. Cho, K. W. Kim, J. Y. Juhn, S. Y. Hwang, C. H. Yoon, S. H. Park, S. H. Lee, and H.-Y. Kim. 2007. Up-regulation of IL-23p19 expression in rheumatoid arthritis synovial fibroblasts by IL-17 through PI3- kinase-, NF-κB- and p38 MAPK-dependent signalling pathways. Rheumatology (Oxford) 46: 57-64.
9. Liu, F. L., C. H. Chen, S. J. Chu, J. H. Chen, J. H. Lai, H. K. Sytwu, and D. M. Chang. 2007. Interleukin (IL)-23 p19 expression induced by IL-1β in human fibroblast-like synoviocytes with rheumatoid arthritis via active nuclear factor-κB and AP-1 dependent pathway. Rheumatology (Oxford) 46: 1266-1273.
10. Langowski, J. L., X. Zhang, L. Wu, J. D. Mattson, T. Chen, K. Smith, B. Basham, T. McClanahan, R. A. Kastelein, and M. Oft. 2006. IL-23 promotes tumour incidence and growth. Nature 442: 461-465. (Pubitemid 44264796)
11. Martin-Orozco, N., and C. Dong. 2009. The IL-17/IL-23 axis of inflammation in cancer: friend or foe? Curr. Opin. Investig. Drugs 10: 543-549.
12. Carmody, R. J., Q. Ruan, H. C. Liou, and Y. H. Chen. 2007. Essential roles of c- Rel in TLR-induced IL-23 p19 gene expression in dendritic cells. J. Immunol. 178: 186-191.
13. Mise-Omata, S., E. Kuroda, J. Niikura, U. Yamashita, Y. Obata, and T. S. Doi. 2007. A proximal kB site in the IL-23 p19 promoter is responsible for RelA- and c-Rel-dependent transcription. J. Immunol. 179: 6596-6603.
14. Liu, W., X. Ouyang, J. Yang, J. Liu, Q. Li, Y. Gu, M. Fukata, T. Lin, J. C. He, M. Abreu, et al. 2009. AP-1 activated by Toll-like receptors regulates expression of IL-23 p19. J. Biol. Chem. 284: 24006-24016.
15. Al-Salleeh, F., and T. M. Petro. 2008. Promoter analysis reveals critical roles for SMAD-3 and ATF-2 in expression of IL-23 p19 in macrophages. J. Immunol. 181: 4523-4533.
16. Blackshear, P. J. 2002. Tristetraprolin and other CCCH tandem zinc-finger proteins in the regulation of mRNA turnover. Biochem. Soc. Trans. 30: 945-952.
17. Lai, W. S., E. Carballo, J. R. Strum, E. A. Kennington, R. S. Phillips, and P. J. Blackshear. 1999. Evidence that tristetraprolin binds to AU-rich elements and promotes the deadenylation and destabilization of tumor necrosis factor α mRNA. Mol. Cell. Biol. 19: 4311-4323.
18. Carballo, E., W. S. Lai, and P. J. Blackshear. 2000. Evidence that tristetraprolin is a physiological regulator of granulocyte-macrophage colony-stimulating factor messenger RNA deadenylation and stability. Blood 95: 1891-1899.
19. Sawaoka, H., D. A. Dixon, J. A. Oates, and O. Boutaud. 2003. Tristetraprolin binds to the 39-untranslated region of cyclooxygenase-2 mRNA: a poly-adenylation variant in a cancer cell line lacks the binding site. J. Biol. Chem. 278: 13928-13935.
20. Ogilvie, R. L., M. Abelson, H. H. Hau, I. Vlasova, P. J. Blackshear, and P. R. Bohjanen. 2005. Tristetraprolin down-regulates IL-2 gene expression through AU-rich element-mediated mRNA decay. J. Immunol. 174: 953-961.
21. Stoecklin, G., S. A. Tenenbaum, T. Mayo, S. V. Chittur, A. D. George, T. E. Baroni, P. J. Blackshear, and P. Anderson. 2008. Genome-wide analysis identifies interleukin-10 mRNA as target of tristetraprolin. J. Biol. Chem. 283: 11689-11699.
22. Datta, S., R. Biswas, M. Novotny, P. G. Pavicic, Jr., T. Herjan, P. Mandal, and T. A. Hamilton. 2008. Tristetraprolin regulates CXCL1 (KC) mRNA stability. J. Immunol. 180: 2545-2552.
23. Carballo, E., W. S. Lai, and P. J. Blackshear. 1998. Feedback inhibition of macrophage tumor necrosis factor-a production by tristetraprolin. Science 281: 1001-1005.
24. Phillips, K., N. Kedersha, L. Shen, P. J. Blackshear, and P. Anderson. 2004. Arthritis suppressor genes TIA-1 and TTP dampen the expression of tumor necrosis factor a, cyclooxygenase 2, and inflammatory arthritis. Proc. Natl. Acad. Sci. USA 101: 2011-2016.
25. Taylor, G. A., E. Carballo, D. M. Lee, W. S. Lai, M. J. Thompson, D. D. Patel, D. I. Schenkman, G. S. Gilkeson, H. E. Broxmeyer, B. F. Haynes, and P. J. Blackshear. 1996. A pathogenetic role for TNFα in the syndrome of cachexia, arthritis, and autoimmunity resulting from tristetraprolin (TTP) deficiency. Immunity 4: 445-454.
26. Sauer, I., B. Schaljo, C. Vogl, I. Gattermeier, T. Kolbe, M. Müller, P. J. Blackshear, and P. Kovarik. 2006. Interferons limit inflammatory responses by induction of tristetraprolin. Blood 107: 4790-4797. (Pubitemid 43882630)
27. Nakae, S., A. Nambu, K. Sudo, and Y. Iwakura. 2003. Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J. Immunol. 171: 6173-6177. (Pubitemid 37467240)
28. Stumhofer, J. S., A. Laurence, E. H. Wilson, E. Huang, C. M. Tato, L. M. Johnson, A. V. Villarino, Q. Huang, A. Yoshimura, D. Sehy, et al. 2006. Interleukin 27 negatively regulates the development of interleukin 17-producing T helper cells during chronic inflammation of the central nervous system. Nat. Immunol. 7: 937-945.
29. Batten, M., J. Li, S. Yi, N. M. Kljavin, D. M. Danilenko, S. Lucas, J. Lee, F. J. de Sauvage, and N. Ghilardi. 2006. Interleukin 27 limits autoimmune encephalomyelitis by suppressing the development of interleukin 17-producing T cells. Nat. Immunol. 7: 929-936.
30. Aggarwal, S., and A. L. Gurney. 2002. IL-17: prototype member of an emerging cytokine family. J. Leukoc. Biol. 71: 1-8.
31. Fossiez, F., O. Djossou, P. Chomarat, L. Flores-Romo, S. Ait-Yahia, C. Maat, J. J. Pin, P. Garrone, E. Garcia, S. Saeland, et al. 1996. T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J. Exp. Med. 183: 2593-2603.
32. Jones, C. E., and K. Chan. 2002. Interleukin-17 stimulates the expression of interleukin-8, growth-related oncogene-α, and granulocyte-colony- stimulating factor by human airway epithelial cells. Am. J. Respir. Cell Mol. Biol. 26: 748-753.
33. Ye, P., F. H. Rodriguez, S. Kanaly, K. L. Stocking, J. Schurr, P. Schwarzenberger, P. Oliver, W. Huang, P. Zhang, J. Zhang, et al. 2001. Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense. J. Exp. Med. 194: 519-527.
34. Kolls, J. K., S. T. Kanaly, and A. J. Ramsay. 2003. Interleukin-17: an emerging role in lung inflammation. Am. J. Respir. Cell Mol. Biol. 28: 9-11.
35. Moseley, T. A., D. R. Haudenschild, L. Rose, and A. H. Reddi. 2003. Interleukin- 17 family and IL-17 receptors. Cytokine Growth Factor Rev. 14: 155-174.
36. Tato, C. M., and D. J. Cua. 2008. Reconciling id, ego, and superego within interleukin- 23. Immunol. Rev. 226: 103-111.
37. H-17 cells. Nat. Immunol. 10: 167-175.
38. Zhang, J., X. Qian, H. Ning, J. Yang, H. Xiong, and J. Liu. 2010. Activation of IL-27 p28 gene transcription by interferon regulatory factor 8 in cooperation with interferon regulatory factor 1. J. Biol. Chem. 285: 21269-21281.
39. Liu, J., S. Cao, L. M. Herman, and X. Ma. 2003. Differential regulation of interleukin (IL)-12 p35 and p40 gene expression and interferon (IFN)-γ-primed IL-12 production by IFN regulatory factor 1. J. Exp. Med. 198: 1265-1276.
40. Lasa, M., K. R. Mahtani, A. Finch, G. Brewer, J. Saklatvala, and A. R. Clark. 2000. Regulation of cyclooxygenase 2 mRNA stability by the mitogen-activated protein kinase p38 signaling cascade. Mol. Cell. Biol. 20: 4265-4274.
41. Lee, J. C., and P. R. Young. 1996. Role of CSB/p38/RK stress response kinase in LPS and cytokine signaling mechanisms. J. Leukoc. Biol. 59: 152-157.
42. Anderson, P., K. Phillips, G. Stoecklin, and N. Kedersha. 2004. Post-transcriptional regulation of proinflammatory proteins. J. Leukoc. Biol. 76: 42-47.
43. Sheikh, S. Z., K. Matsuoka, T. Kobayashi, F. Li, T. Rubinas, and S. E. Plevy. 2010. Cutting edge: IFN-γ is a negative regulator of IL-23 in murine macrophages and experimental colitis. J. Immunol. 184: 4069-4073.
44. Schichl, Y. M., U. Resch, R. Hofer-Warbinek, and R. de Martin. 2009. Tristetraprolin impairs NF-κB/p65 nuclear translocation. J. Biol. Chem. 284: 29571-29581.
45. Liang, J., T. Lei, Y. Song, N. Yanes, Y. Qi, and M. Fu. 2009. RNA-destabilizing factor tristetraprolin negatively regulates NF-κB signaling. J. Biol. Chem. 284: 29383-29390.
46. Anderson, P. 2008. Post-transcriptional control of cytokine production. Nat. Immunol. 9: 353-359.